The NAD+ Bottleneck: An Energy Crisis Before Symptoms

Experiment #10 | July 2, 2026

Experiment Card

EXP-010-NAD-METABOLIC

Date

2026-07-02

Type

Metabolic / NAD+ Analysis

Status

Complete

Run

Model: Gemma 4 (local)

Papers: 81 (65 high-relevance)

Hypotheses: 3

Cost: $0 (local)

The Question

Is NAD+ depletion — caused by an overworked DNA-repair enzyme (PARP1) burning through the cell's NAD+ supply — a pre-symptomatic metabolic bottleneck in Huntington's Disease?

Lead candidate

Nicotinamide Riboside — 95/100

And it's already in a Phase 2 HD trial (NCT06853743, recruiting)

The Mechanism: Why the Energy Runs Out

This experiment supplies the missing mechanism behind the NAD+ signal that surfaced across earlier experiments. HD neurons have impaired double-strand-break repair, which chronically over-activates PARP1 — an enzyme that consumes NAD+ as fuel. The result is an NAD+ shortage that starves mitochondria and the SIRT1 axis, before neurons visibly die.

Root

Impaired DNA repair in HD neurons

HTT interactome disrupts double-strand-break repair (PMID 41850723)

↓

Drain

PARP1 hyperactivation burns NAD+

Poly-ADP-ribose signaling dysregulated in HD (PMID 39331414)

↓

Consequence

Mitochondrial + SIRT1 failure

Energy deficit, lost antioxidant defense, neuron vulnerability

The intervention

Refill the tank: NAD+ precursors (NR/NMN) restore the supply, or PARP inhibitors stop the drain upstream. NR is already being tested in HD patients.

Top Drug Hypotheses

95/100

Nicotinamide Riboside (NR) / NMN

In Phase 2 HD trial

Target: NAD+ synthesis / mitochondrial stress response

NAD+ precursors restore cellular pools, supporting mitochondrial quality control and the Nrf2/SIRT1 antioxidant axes. Caveat: efficacy depends on blood-brain-barrier penetration; optimal CNS dosing unclear.

85/100

PARP inhibitors (olaparib analogs)

Target: DNA damage response / PARP1 activity

Block the NAD+ drain upstream by inhibiting PARP1 hyperactivation. Caveat: potent agents with systemic side effects (bone-marrow suppression); HD-specific neuroprotection needs validation.

78/100

SIRT1 activators (resveratrol analogs)

Target: metabolic reprogramming / epigenetic regulation

Activate the downstream effector without full NAD+ restoration. Caveat: complex polypharmacology; needs selective CNS activation.

Grounded in reality

This one is already being tested

Unlike most AI hypotheses, the lead candidate here has a live trial: NCT06853743 — a Phase 2 randomized trial of Nicotinamide Riboside in 120 HD patients (Oslo University Hospital, recruiting). Our chatbot can confirm this live: ask it "is nicotinamide riboside in an HD trial?"

Experiment Trail

Exp 7Lipid-proteostasis cascade — lipid disruption first

Exp 8Epigenetic TET1 suppression; predicted an NAD+/SIRT3 link

Exp 9Gut-brain axis as the upstream systemic trigger

Exp 10 ←The NAD+ bottleneck — the mechanism (PARP1) behind the metabolic collapse; NR in a real trial

AI-generated for educational purposes only. Not clinical advice. Candidate drugs (nicotinamide riboside, NMN, PARP inhibitors) are discussed as research hypotheses about NAD+ biology, not treatment recommendations — do not self-medicate. Verify against primary literature. Data: PubMed (last 24 months). Model: Gemma 4, local inference. We are data scientists, not doctors.